Volver a Agenda
Session 5, Track C: AI-Enhanced Pharmacovigilance: Shaping the Future of Drug Safety
Session Chair(s)
Daniel Greco, PharmD, RPh
Associate Director of Patient Safety
Bristol-Myers Squibb Company, Canada
Nadia Mian, MS
Pharmacovigilance Manager
Ipsen Biopharmaceuticals Canada Inc., Canada
The session will explore the transformative impact of artificial intelligence on pharmacovigilance. Attendees will gain insights into how AI is redefining drug safety processes, enhancing efficiency, and ensuring more robust risk management. The discussion will cover fundamental AI concepts, automation models, and critical factors in evaluating AI's suitability for various pharmacovigilance workflows. Additionally, the session will address the potential risks and challenges associated with integrating AI into drug safety operations.
Learning Objective : At the conclusion of this session, participants should be able to:- Define “Artificial Intelligence” and the three models of automation
- Describe key considerations for assessing the potential for automation for a given workflow
-
Identify risks associated with the use of AI
¿Tiene una cuenta?